Investigational drug · Phase 2
Lesigercept
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Allergic Diseases, Chronic Spontaneous Urticaria (CSU).
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Lesigercept"
First trial start
2026
Mar 26, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lesigercept", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Diseases
- Chronic Spontaneous Urticaria (CSU)
Approved drugs for the same conditions: Chronic hives (urticaria) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Lesigercept" as an intervention, largest first.
- Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-AntihistaminesPivotal-lookingRecruiting
Yuhan CorporationIndustry
NCT07415551 · 150 participants (planned) · Start Mar 26, 2026 · Primary completion Jun 19, 2027
Drug: Lesigercept; Placebo · For: Allergic Diseases; Chronic Spontaneous Urticaria (CSU)
Sites: Sofia, Bulgaria; Guangzhou, China; Shenzhen, China · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases.
Cho YS, Ye YM, Lee SY, et al. · Int Immunopharmacol 2026
Also in development for Allergic Diseases
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.